A study by Decision Resources Group finds that the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8 percent annual growth) in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This impressive growth will be driven by the expected market entry of nine novel immunotherapies—including four novel immune checkpoint inhibitors and five novel therapeutic vaccines—in new oncology indications and/or patient populations. Taken together, Bristol-Myers Squibb's anti-CTLA-4 agent Yervoy and novel immune checkpoint inhibitors that target the anti-programmed cell death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway—including Bristol-Myers Squibb/Ono Pharmaceutical's nivolumab, Merck & Co.'s pembrolizumab (MK-3475), Roche/Genentech/Chugai's MPDL-3280A and AstraZeneca/MedImmune's MEDI4736—will dominate the immunotherapy market and capture a staggering 85 percent market share in 2022.
